Clinical Trial Update: An Open Label Phase II Study of Biweekly Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Prostatic Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase II open-label study evaluating biweekly docetaxel with androgen-deprivation therapy in previously untreated metastatic prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer
• Prostatic Neoplasm

Drugs mentioned

• Androgen deprivation therapy (Androgen deprivation therapy)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Samsung Medical Center | Conditions: Prostatic Neoplasm | Phase 2 | Status: UNKNOWN